Ahmad Saltagi, MD
Pulmonary Disease · Noblesville, INNPI 1417927039
Payments from drug & device makers
Across 963 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Sanofi$1K
- Boehringer Ingelheim$1K
- Takeda Pharmaceuticals U.S.A., Inc.$938
- Regeneron Healthcare Solutions, Inc.$922
- plus $8K from 49 others
What the payments were for
- Food & beverage$16,76797%
- Education$4593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$109
How this compares
$17,226 in reported general payments places this provider in the 85th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 30 | $369,874 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 246 | $279,462 |
| GlassiaAlpha-1-Proteinase Inhibitor | 25 | $251,944 |
| OfevNintedanib Esylate | 17 | $224,694 |
| AdempasRiociguat | 12 | $162,687 |
| Dupixent PenDupilumab | 29 | $114,533 |
| XolairOmalizumab | 29 | $80,185 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $65,375 |
| Orenitram ErTreprostinil Diolamine | 24 | $48,996 |
| NucalaMepolizumab | 13 | $48,014 |
| Breo ElliptaFluticasone/Vilanterol | 85 | $47,375 |
| Spiriva RespimatTiotropium Bromide | 35 | $36,172 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $31,003 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $28,182 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 144 | $23,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,428 | $406,483389 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $538 | $369,87430 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,052 | $304,114111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $938 | $251,94425 claims |
| BayerAdempas | $135 | $162,68712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,303 | $93,557119 claims |
| PfizerEliquis | $218 | $22,02632 claims |
| MerckDulera | $92 | $12,67916 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $218 | $3,05211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Noblesville
- Muhammad HabibNoblesville$235K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Faisal KhanGreenwood$400K
- Sandeep KukrejaGreenwood$375K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.